ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Zinc fingers to touch Gilead therapies

by Ryan Cross
March 5, 2018 | APPEARED IN VOLUME 96, ISSUE 10

Gilead Sciences is betting big on gene editing to improve its cell immunotherapy programs. But rather than embrace CRISPR, Gilead has partnered with Sangamo Therapeutics, a pioneer of an older gene-editing tool called the zinc finger nuclease (ZFN). Sangamo has amassed a large ZFN protein library, allowing it to link ZFNs together to target any site in the genome. Gilead will give Sangamo $150 million up front and up to $3 billion more if Gilead develops 10 or more new therapies.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment